# Grifols Therapeutics LLC clinical trials: 46 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 46 trials with Grifols Therapeutics LLC as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Grifols Therapeutics LLC: 46 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/grifols-therapeutics-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 46
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 46, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 29, 2026 | NCT07555483 | A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With... | Grifols Therapeutics LLC | Phase 3 | Recruiting | Alpha 1 Antitrypsin Deficiency | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555483) |
| April 20, 2026 | NCT07540221 | A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating... | Grifols Therapeutics LLC | Phase 3 | Recruiting | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07540221) |
| December 9, 2022 | NCT05645107 | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in... | Grifols Therapeutics LLC | Phase 3 | Recruiting | Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05645107) |
| April 19, 2021 | NCT04847141 | A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients | Grifols Therapeutics LLC | Phase 3 | Terminated | COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04847141) |
| January 25, 2021 | NCT04722887 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human)... | Grifols Therapeutics LLC | Phase 1/2 | Completed | Alpha1-Antitrypsin Deficiency | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04722887) |
| September 28, 2020 | NCT04566692 | A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve... | Grifols Therapeutics LLC | Phase 4 | Completed | Primary Immunodeficiency | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04566692) |
| September 23, 2020 | NCT04561115 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG)... | Grifols Therapeutics LLC | Phase 3 | Completed | Primary Immunodeficiency | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04561115) |
| September 14, 2020 | NCT04547140 | Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus... | Grifols Therapeutics LLC | Phase 2 | Terminated | COVID-19 | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04547140) |
| July 21, 2020 | NCT04480424 | Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT... | Grifols Therapeutics LLC | Phase 2 | Completed | COVID-19 | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04480424) |
| January 24, 2019 | NCT03814798 | Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency | Grifols Therapeutics LLC | Phase 3 | Withdrawn | Primary Immunodeficiency | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03814798) |
| March 1, 2018 | NCT03451292 | Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites | Grifols Therapeutics LLC | Phase 3 | Completed | Decompensated Cirrhosis and Ascites | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03451292) |
| November 24, 2017 | NCT03351933 | Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) | Grifols Therapeutics LLC | Phase 4 | Completed | Anti-Hepatitis A Antibody Levels in Heathy Subjects | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03351933) |
| March 29, 2017 | NCT03095287 | Alphanate in Immune Tolerance Induction Therapy | Grifols Therapeutics LLC | Phase 2 | Terminated | Hemophilia A, Congenital | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03095287) |
| August 19, 2016 | NCT02872142 | Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis | Grifols Therapeutics LLC | Phase 2 | Completed | Amyotrophic Lateral Sclerosis | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02872142) |
| August 17, 2016 | NCT02870348 | Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) | Grifols Therapeutics LLC | Phase 1/2 | Completed | Alpha1-Antitrypsin Deficiency | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02870348) |
| August 17, 2016 | NCT02870309 | Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin... | Grifols Therapeutics LLC | Phase 1/2 | Completed | Alpha1-Antitrypsin Deficiency | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02870309) |
| June 21, 2016 | NCT02806986 | Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency | Grifols Therapeutics LLC | Phase 3 | Completed | Primary Immunodeficiency | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02806986) |
| June 13, 2016 | NCT02796937 | Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency | Grifols Therapeutics LLC | Phase 3 | Enrolling by invitation | Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | 290 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02796937) |
| November 13, 2015 | NCT02604810 | Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency | Grifols Therapeutics LLC | Phase 3 | Completed | Primary Immunodeficiency | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02604810) |
| June 17, 2015 | NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | Grifols Therapeutics LLC | Phase 2 | Completed | Myasthenia Gravis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02473965) |
| June 17, 2015 | NCT02473952 | A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis | Grifols Therapeutics LLC | Phase 2 | Completed | Myasthenia Gravis, Generalized | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02473952) |
| June 16, 2015 | NCT02472665 | Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease | Grifols Therapeutics LLC | Phase 4 | Withdrawn | Von Willebrand Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02472665) |
| April 10, 2015 | NCT02413580 | A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations | Grifols Therapeutics LLC | Phase 3 | Completed | Myasthenia Gravis Exacerbations | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02413580) |
| November 4, 2014 | NCT02282527 | A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency | Grifols Therapeutics LLC | Phase 2/3 | Completed | Alpha₁-Antitrypsin Deficiency | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02282527) |
| November 3, 2014 | NCT02281500 | Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia | Grifols Therapeutics LLC | Phase 1/2 | Completed | Congenital Afibrinogenemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02281500) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 1/2 | 5 |
| Phase 2 | 17 |
| Phase 2/3 | 1 |
| Phase 3 | 16 |
| Phase 4 | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 35 |
| Terminated | 5 |
| Recruiting | 3 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| alpha 1-Antitrypsin Deficiency | 12 |
| Primary Immunodeficiency Diseases | 8 |
| Pulmonary Emphysema | 6 |
| COVID-19 | 3 |
| Immunologic Deficiency Syndromes | 3 |
| Emphysema | 3 |
| Agammaglobulinemia | 2 |
| Cystic Fibrosis | 2 |
| Thrombosis | 2 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2 |
| Myasthenia Gravis | 2 |
| Pathologic Processes | 2 |
| Pulmonary Disease, Chronic Obstructive | 2 |
| Lung Diseases, Obstructive | 2 |
| Lung Diseases | 2 |
| Respiratory Tract Diseases | 2 |
| Genetic Diseases, Inborn | 2 |
| Subcutaneous Emphysema | 2 |
| Ascites | 1 |
| Coronavirus Infections | 1 |
| Coronaviridae Infections | 1 |
| Virus Diseases | 1 |
| Congenital lobar emphysema | 1 |
| Infections | 1 |
| Bacterial Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Telephone service providers in the United States](https://specstream.ai/data/businesses/telephone-service-providers/united-states)
- [Valet services in the United States](https://specstream.ai/data/businesses/valet-services/united-states)
- [Wine wholesalers in the United States](https://specstream.ai/data/businesses/wine-wholesalers/united-states)
- [Armenian restaurants in the United States](https://specstream.ai/data/businesses/armenian-restaurants/united-states)
- [B2B power plants and power plant companies in the United States](https://specstream.ai/data/businesses/b2b-power-plants-and-power-plant-companies/united-states)
- [Bookkeeping firms in the United States](https://specstream.ai/data/businesses/bookkeeping-firms/united-states)
